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MODULAR ANALYTICS (Roche Diagnostics) (MODULAR ANALYTICS, Elecsys and Cobas Integra are trademarks of a mem-
ber of the Roche Group) represents a new approach to automation for the clinical chemistry laboratory. It consists of a control
unit, a core unit with a bidirectional multitrack rack transportation system, and three distinct kinds of analytical modules: an
ISE-module, a P800 module (44 photometric tests, throughput of up to 800 tests/h), and a D2400 module (16 photometric tests,
throughput up to 2400 tests/h). MODULAR ANALYTICS allows customised conﬁgurations for various laboratory workloads. The
performance and practicability of MODULAR ANALYTICS were evaluated in an international multicentre study at 16 sites. Stud-
ies included precision, accuracy, analytical range, carry-over, and workﬂow assessment. More than 700000 results were obtained
during the course of the study. Median between-day CVs were typically less than 3% for clinical chemistries and less than 6% for
homogeneous immunoassays. Median recoveries for nearly all standardised reference materials were within 5% of assigned values.
Method comparisons versus current existing routine instrumentation were clinically acceptable in all cases. During the workﬂow
studies, the work from three to four single workstations was transferred to MODULAR ANALYTICS, which oﬀered over 100
possible methods, with reduction in sample splitting, handling errors, and turnaround time. Typical sample processing time on
MODULAR ANALYTICS was less than 30 minutes, an improvement from the current laboratory systems. By combining multiple
analytic units in ﬂexible ways, MODULAR ANALYTICS met diverse laboratory needs and oﬀered improvement in workﬂow over
current laboratory situations. It increased overall eﬃciency while maintaining (or improving) quality.
1. INTRODUCTION
At the beginning of the 21st century, clinical laboratories are
faced with many challenges, including reduced fee schedules,
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demands for faster turnaround times, diminished numbers
of qualiﬁed technologists, and requests for larger test reper-
toires. To meet these challenges, laboratories are relying in-
creasingly on automation.
Traditionally, automating a manual test has allowed for
better precision and accuracy, faster turnaround time, and
around-the-clock availability. Currently, in most laborato-
ries,many,ifnotmost,samplesmustbeplacedonseveraldif-
ferent automated instruments to complete all of the orderedMODULAR ANALYTICS 9
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Figure 1: Schematic structure of MODULAR.
tests. Although this represents an advance over manual test-
ing, it is an inherently ineﬃcient process, as each instrument
requires its own operators, training courses, reagent systems,
maintenance schedules, and proﬁciency testing.
One approach to enhancing laboratory eﬃciency has
been to attach multiple disparate analysers with a series of
conveyor belts or similar transport systems [1]. In these sys-
tems, one still has the ineﬃciency of diﬀerent instruments
(not to mention yet another layer of software) but one gains
eﬃciency from not having to manually transport samples
from one instrument to another.
MODULAR ANALYTICS from Roche Diagnostics
GmbH, Mannheim, Germany, hereafter MODULAR, rep-
resents a diﬀerent approach to automation. By assembling
multiple analyser modules with standardised dimensions
and interfaces, MODULAR acts more like a single analyser,
even though it can be customised by the choice of mod-
ules used, the number of modules used, and the speciﬁc
analytes placed on each module. MODULAR consists of
a control unit, a core unit, and analytical modules. The
control unit is a Microsoft Windows NT-based personal
computer (PC), from which a single operator can control
the entire system. The core unit consists of a bidirectional
multitrack transportation system (BMTS) together with a
loader/unloader and a rerun buﬀer. The BMTS is a unique
feature of MODULAR, consisting of a main lane, processing
lane, and rerun lane, that eliminates queuing of sample racks
as they travel between analytical modules. As indicated in
Figure 1, sample racks, containing up to ﬁve tubes each,
are conveyed to modules by the main lane, where they can
be transferred to the processing lane. After the sampling
process, the rack is returned to the main lane and then
conveyed to the next module or to the rerun buﬀer. The rack
remains in the rerun buﬀer until all test results for those
samples are available, at which time the rack is transported
either to the unloader or back to the modules where reruns
are needed.
We evaluated three kinds of analytical modules: an elec-
trolyte module (ISE900), an 800 tests/h maximum through-
put photometric module with an on-board capacity of 44
tests (P800), and a 2400 tests/h maximum throughput pho-
tometric module with an on-board capacity of 16 tests
(D2400) (abbreviated to ISE-, P-, and D-module, resp., in
the following text). The main speciﬁcations are presented
in Table 1. As noted earlier, MODULAR can be conﬁgured
with analytical modules in several diﬀerent ways (e.g., ISE
+ P + D, ISE + P + P, etc.). In addition, a large num-
ber of diﬀerent chemistries can be placed on the photo-
metric modules (examples are shown in Table 2). Because
of the number of on-board chemistries available per mod-
ule as well as the breadth of this test repertoire, MODU-
LAR can process most serum tests and thereby eliminate
the need for separate laboratory classiﬁcations such as clin-
ical chemistry, immunology, and therapeutic drug monitor-
ing.
2. MATERIALS AND METHODS
This study consisted of two parts: detailed analytical per-
formance experiments at ﬁve sites, followed by functionality
and practicability experiments at all 16 sites, including hard-
ware evaluation, software evaluation, and chemistry inter-
actions during simulated routine operating conditions. For
most sites, the standard MODULAR conﬁguration was one
ISE-module, one D-module, and one P-module. MODU-
LAR reagents and calibrators were supplied by Roche Di-
agnostics in system packs containing bar coded bottles. Im-
precision and quality control studies were performed with
lyophilised control sera from Roche Diagnostics and con-
trol urines from BioRad (BioRad Laboratories, Irvine, Calif,
USA). Standardised reference materials were obtained from
the National Institute of Standards & Technology (NIST,
Washington, DC, USA) and from the Community Bureau of
Reference (Brussels).10 Journal of Automated Methods & Management in Chemistry
Table 1: Main speciﬁcations of MODULAR ANALYTICS.
Items Speciﬁcation
Method Discrete method of simultaneous analysis for multiple tests according to analyser module
combinations
Method of sample loading Continuous loading of ﬁve-position racks
Numberofbatchesforracks 300 samples (in 2 trays)
Rack processing method Distribution method in which the racks are captured by the various analyser modules as
determined by the Intelligent Process Manager. Intelligent process management ensures
most eﬃcient operation, whereby racks are processed in serial, parallel, or serial/parallel
mode with full by-pass function and automatic rerun
Number of items
for analysis
Maximum of 100 items: photometric (86 tests) + calculation test (8 tests) + blood serum
indexes (3 tests) + electrolyte (3 tests)
Assay method 1-point end, 2-point end, 3-point rate, 3-point, rate A, rate B
Calibration Linear, k-factor, isozyme, nonlinear methods
Nonlinear function = maximum of 6 points
4-parameter logit-log, 5-parameter logit-log, 5-parameter exponential function, spline
function, polygonal line working curve
Monitoring functions Such as reaction process monitoring, data review, working curve, and calibration rates
Quality control Real-time quality control, quality control for samples within a day and between days
Retesting function Automatic and manual retests are available
Control unit Windows NT based user interface, touch screen and mouse operation, remote diagnostic
access
Number of tests for
simultaneous analysis
D
P
ISE
Maximum of 16
Maximum of 44 tests
Maximum of 3 tests (Na, K, Cl)
Processing capability D
P
ISE
Maximum of 2400 tests/h
Maximum of 800 tests/h
Maximum of 900 tests/h
Sample pipetting volume D
P
ISE
2∼20 µL/test (in 0.1 µL steps)
2∼35 µL/test (in 0.1 µL steps)
15 µL/test
Reagent pipetting and
reaction volume
D/P 20∼270 µL/test (in 1 µL steps) reagent pipetting, 180∼380 µL reaction volume
Reaction disk D
P
Turntable method, each 240 reaction cuvettes inside and outside circumferences
Turntable method, 160 reaction cuvettes
Reaction time D
P
10min
1∼10min (in 1min steps)
Photometer D/P Concave diﬀraction grating multiwavelengths photometer (12 wavelengths), 0∼3A B S( 2
units on D-module)
The protocols for the detailed analytical performance ex-
periments in general followed the ECCLS and NCCLS guide-
lines [2, 3] and are summarised in Table 3 [4, 5, 6, 7, 8, 9].
The instruments used for comparison purposes were mainly
Roche/Hitachi 747 (in three laboratories) and Roche/Hitachi
917 (in two laboratories). In all, as indicated in Table 2,
34 analytes covering 45 diﬀerent methods were tested, with
representative assays for all analyte groups from the manu-
facturer’s available test menu.
The protocols for functionality and practicability ex-
periments are summarised in Table 4 [10, 11]. These stud-
ies focused on precision while running a normal work-
load, comparisons to existing methods, and practicabil-
ity as assessed by a detailed questionnaire. In addition,
some laboratories undertook detailed workﬂow studies. Up
to 40 analytes were processed at each site, encompass-
ing a total of 65 diﬀerent analytes and 81 diﬀerent meth-
ods.MODULAR ANALYTICS 11
Table 2: Analyte selection.
Enzymes Protocol Proteins Protocol
ALP Alkaline phosphatase AMP a & b A1M α1-Microglobulin TIA a & b
ALPO Alkaline phosphatase DGKCh b ALBU Albumin in urine TIA a & b
ALT Alanine aminotransferase IFCC b ASLO Antistreptolysin O LPIA b
AMYL Amylase total liquid EPS a & b B2M β2-Microglobulin TIA b
PAMY Amylase pancreatic liquid EPS b CRP C-reactive protein TIA a & b
AST Aspartate aminotransferase IFCC a & b FERRI Ferritin LPIA a & b
CHE Cholinesterase Butyryl b GPROT α1-Glycoprotein TIA b
CK CK NAC act a & b HBA1c Glycated Haemoglobin TIA a & b
CK-MB Creatine kinase MB a & b HGLOB Haptoglobin TIA b
GGT γ-Glutamyl transferase Szasz b IGA Immunoglobulin A, TIA a & b
LD Lactate dehydrogenase (L→P) b IGG Immunoglobulin G, TIA a & b
LD-1 Lactate dehydrogenase isoenzyme 1 b IGM Immunoglobulin M, TIA a & b
LDHO Lactate dehydrogenase DGKCh a & b MYO Myoglobin TIA a & b
LDHS Lactate dehydrogenase SFBC b RF Rheumatoid factor LPIA b
LIP Lipase colorimetric a & b TRANS Transferrin TIA b
U/CSF Protein in urine/CSF turbidim b
Substrates/electrolytes Protocol TDM/others Protocol
ALB Albumin BCG (plus) a & b CARB Carbamazepine Cedia b
CHOL Cholesterol CHOD-PAP a & b DIG Digoxin LPIA a & b
CRE+ Creatinine enzymatic (plus) a & b; c GENTA Gentamicin Cedia b
CREJ Creatinine Jaﬀ´ e a & b; c NAPA N-acetyl-procainamide Cedia b
DBIL Bilirubin direct Jendrassik b PHEBA Phenobarbital Cedia b
TBIL Bilirubin total DPD b PHENY Phenytoin Cedia b
ETH Blood alcohol ADH b PROCAI Procainamide Cedia b
FRUC Fructosamine b SALY Salicylate Iron complex b
GLUK Glucose HK a & b THEO Theophylline Cedia a & b
GLUP Glucose GOD-PAP b TOBR Tobramycin Cedia b
HDL HDL cholesterol liquid a & b VALP Valproic acid Cedia b
LDL LDL cholesterol liquid b AT III Antithrombin III b
LACT Lactate w/o deproteinization colorimetric b T4 Thyroxine Cedia b
NH3 Ammonia UV b T-UP T-Uptake Cedia b
TG Triacylglycerol GPO-PAP a & b
TP Total protein Biuret a & b
UA Uric acid PAP a & b; c
UIBC Unsaturated iron binding capacity b
UREA Urea (BUN) kinetic UV a & b; c
CA Calcium OCPC a & b; c
CO2 B i c a r b o n a t ek i n e t i cU V a&b
FE Iron ferrozine a & b
MG Magnesium xylidyl blue a & b
PHOS Phosphorus molybdate, UV a & b; c
Na, K, Cl Sodium, potassium, Chloride; indirect ISE a & b; c
a: analytical performance protocol (45 methods for 34 analytes).
b: functional performance and practicability protocol (81 methods for 65 analytes).
c: two applications (serum/plasma and urine).
At the evaluators’ ﬁrst meeting, a set of expected perfor-
mance criteria were agreed upon (Table 5). CV limits were
d e ﬁ n e df o rg r o u p so fa n a l y t e sa tc o n c e n t r a t i o n sn e a rt h e
medical decision level. The criteria for imprecision were de-
signed to take into account state-of-the-art performance,
routine service requirements of the laboratory, and statisti-
cal error propagation [12].
The study was supported by CAEv, a program for “Com-
puter Aided Evaluation” [13], which allows the deﬁnition of
protocols, the sample and test requests for online (and oﬀ-
line) data capture, and statistical evaluation of the results.
Data were validated by the evaluators and transferred elec-
tronically to the central study organisation at Roche Diag-
nostics in Mannheim, Germany.12 Journal of Automated Methods & Management in Chemistry
Table 3: Evaluation protocol of the analytical performance study.
Imprecision Within-run
Performed on three days, each day one run with 21 aliquots. Two control materials (serum, urine) with
diﬀerent concentrations of the analyte and one human specimen pool at the diagnostic decision level were
used.ThemethodstestedwereALP,AMYL,AST,CK,LDH,LIP,ALB,CHOL,CREAJ,CREA+,GLU,TG,TP,
UA, UREA, CA, CO2,FE,MG,PHOS,andCRPonbothD-andP-modules;HDL,CK-MB,FERRI,MYOGB,
IGA, G, M, HBA1C, DIGOX, THEO in serum/plasma and A1M, ALB, CA, CREA+, CREA J, PHOS, UA,
UREA in urine on P-module only; NA, K and CL in serum/plasma and urine on the ISE-module
Between-day
Two control materials with diﬀerent concentrations of the analyte, over 21 days were used. Precision is
derived from the second of triplicate measurements. The methods investigated were the same as for the
within-run experiments
Functional sensitivity [4]
Three serum pools were diluted to ﬁve diﬀerent concentration levels of the analyte which were aliquoted
to ten samples and stored at −20◦C. The concentrations of the aliquots were determined over ten days in
triplicates. Methods investigated: Ferritin on P-module only
Drift Two control sera and the calibrator were determined every half an hour during eight hours, and then in
addition after 24 hours on D-module for selected analytes (CO2, CA, FE, and CRP) to conﬁrm the stability
in the reagent lines. At zero hour the base value was determined as the median of triplicate measurements.
The percentage recovery from the base value was taken as the measure for drift eﬀects. The drift behaviour
was tested with 11 methods on D- and P-modules: AST, CK, CHOL, CREA J, GLUC-HK, TP, UA, CO2,C A ,
FE, and CRP, two methods on the P-module only: DIG, THEO, and three methods on the ISE-module: NA,
K, and CL
Analytical range limits Protocol is based on [5]
Mixing of a high-level with a low level specimen led to a dilution series of 11 concentration steps with nine
dilution steps plus two basic concentrations. Triplicate measurements of samples from the 11 concentration
steps were performed and the median for each step was calculated. The regression line (Passing/Bablok
regression [6]) was calculated using values of ﬁve concentrations, the range of which was assumed to be
linear. The target values for all concentration steps were calculated from the regression lines
Methods investigated: AST, CK, CHOL, CREA J, GLU, TP, UA, CA, CO2, FE, and CRP on both D- and P-
modules; HDL, FERRI, MYOGB, IGA, G, M, in serum/plasma and A1M, ALB, CA, CREA+, CREA J, PHOS,
UA, UREA in urine on P-module only; NA, K, and CL in serum/plasma and urine on the ISE-module
Carry-over Sample related
Model of Broughton [7]
Measurements of three aliquots of a high-concentration sample (h1 ···h3) were followed by measurements
of ﬁve aliquots of a low-concentration sample (l1 ···l5). This series was repeated 10 times. If a carry-over
eﬀectexists,l1 isthemostinﬂuenced,l5 theleastinﬂuencedaliquot.Thesample-relatedcarry-over—median
(l1 − l5)—was compared with the imprecision of the low-concentration sample. Methods investigated: CK
and ferritin (analytes having a wide physiologic range) and urine versus serum for creatinine and albumin
Reagent dependent [8]
Assay A inﬂuences assay B
Carry-over caused by the cuvettes was tested between the triglycerides and lipase assays; the lipoprotein
lipase of the triglycerides assay shows lipase activity.
Test A was pipetted into 21 cuvettes and the analyser was stopped. Assay B was performed in 42 cuvettes; the
ﬁrst 21 determinations might be inﬂuenced by assay A, the last 21 determinations were uninﬂuenced. The
diﬀerence of the medians of both series is the carry-over
Carry-over caused by reagent probes and stirrers was tested between the triglycerides and lipase assays and
between a one molar phosphate buﬀer (this is approximately a tenfold higher concentration than is usually
used in the reagents) and the phosphate assay
Assay B was carried out 21 times. In a second step tests A and B were requested 21 times. The carry-over was
the diﬀerence between the medians of both series. The carry-over eﬀects were compared with the impreci-
sion and the diagnostic relevance of assay BMODULAR ANALYTICS 13
Table 3: Continued.
Interference Protocol according to Glick [9]
A serum with concentrations at the relevant decision level was spiked with the interfering substance and a
dilution series of ten dilution steps was prepared with the same baseline serum. The diﬀerent analytes were
measured in triplicates. The concentration of the interfering substance was related to the serum index of the
instrument. The percentage recovery of the baseline value from the corresponding analyte was calculated for
each dilution step
The methods tested were ALP, AST, CK, ALB, CHOL, CREA J, CREA+, GLU, TP, UA, UREA, CA, CO2,F E ,
MG,PHOS,NA,K,CLforconjugatedandunconjugatedbilirubin;AST,CK,CHOL,HDL,CREAJ,CREA+,
GLU, TP, UA, CA, FE, NA, K, CL CRP, FERRI, MYO, IGA, G, M, DIGOX, THEO for lipaemia, and AMYL,
AST, CK, LDH, LIP, CHOL, CREA J, GLU, TG, TP, UA, CA, FE, NA, K, CL for haemolysis
Accuracy Interlaboratory survey
Two control materials with concentrations not known to the evaluators were used for AST, CK, ALB, CHOL,
C R E AJ ,C R E A + ,G L U ,T P ,U A ,U R E A ,C A ,F E ,M G ,P H O S ,N A ,K ,a n dC L .T h ea s s i g n e dv a l u e sf o rs e v -
eral substrate methods were related to reference methods. The median was calculated from the second of
triplicate measurements over ﬁve days
Standardreferencematerials(CRM,NIST)forcertainenzyme,substrate,andelectrolytemethodswereanal-
ysed on one day in triplicate measurements. The methods tested were CHOL, CREA J, CREA+, UA, UREA,
CA, MG, NA, K, and CL in NIST material and AST and CK in the CRM material
Method comparison Fivetoﬁfteenfreshhumanspecimensdependingonanalytesweremeasuredeachdayfor10daysonMODU-
LARandonthecomparisoninstruments.Thespecimenscoveredasmuchoftheanalyticalrangeaspossible.
The methods were compared by calculation of the Passing/Bablok regression line [6]
The methods tested were the same as for the within-run experiment
Table 4: Evaluation protocol of functionality and practicability.
Routine simulation [10] Precision in a simulated routine run
The ﬁrst of these two experiments tests for potential systematic or random errors by comparing the impre-
cision of the reference results (standard batch, n = 15) with that of results from samples run in a pattern
simulating routine sampling (randomised sample requests, n>10). The randomised sample requests were
simulated in CAEv according to each laboratory’s routine sampling pattern. The samples were control ma-
terials or patient sample pools
The second of the two experiments processed at each site included “provocation steps” designed to interrupt
the smooth ﬂow of work. These actions included deliberately running low on reagent, introducing samples
with insuﬃcient volume, and forcing bar code read errors
Practicability Practicability was assessed using a questionnaire with approximately 200 questions covering all important
attributes of an analytical system [11]
The assessment of each attribute was rated according to a scale from 1 to 10. A rating of 1 was deﬁned as
unimportant, useless, or poor; a rating of 10, absolutely necessary or excellent; a rating of 5, acceptable or
comparable to the present laboratory situation
Workﬂow The participating laboratories in the workﬂow study conﬁgured MODULAR according to their speciﬁc
needs. The primary goal for each laboratory was to examine whether MODULAR would meet their require-
mentsforroutineuseintheirlaboratory.RoutineworkloadswerereplicatedandreprocessedonMODULAR
usingCAEvtocapturetherequestseitherdirectlyfromtheroutineanalysersorviaadownloadfromtheLIS.
In lab A, the sample rack processing time (sample rack placement on MODULAR to results available) was
measured with samples arriving at the MODULAR in real time during a routine working day. In lab B, a
24-hour workload was processed as a single large batch, then again as multiple smaller batches (real-time
processing).LabBalsocharacterisedsamplesprocessedthroughautomaticrerun,measuredthesamplepro-
cessing time (equal to rack processing time for STAT samples) when various STAT samples were introduced
through the STAT sample port during the morning workload, and examined maintenance protocols for
maximising MODULAR operation time and operator convenience. Lab C challenged a PP conﬁguration by
continuously loading and processing approximately 1500 samples with requests for 40 diﬀerent analytes in
one run14 Journal of Automated Methods & Management in Chemistry
3. RESULTS
3.1. Imprecision
The within-run coeﬃcient of variation (CV) for nearly all
methods of enzymes, substrates, and electrolytes was below
2%, with typical CVs of 1%. For speciﬁc proteins, drugs,
and urine analytes, typical within-run CVs were between 1%
and 3%. Within-run imprecision on D- and P-modules was
comparable. One speciﬁc set of experiments allowed for the
comparison of imprecision for tests run in a batch mode
versus tests run in a random access mode (Table 4,“ P r e c i -
sion in a simulated routine run”). When compared to a stan-
dard batch run, one would expect imprecision to be higher
in a run designed to simulate routine working conditions
(i.e., in which many analytes are run, on many samples, in
a random access mode). As shown in Figure 2, the CVs ob-
tained on MODULAR in the random request part were only
slightly higher than in the batch part. Of particular note is
the fact that the results for most of the enzyme and substrate
methods were produced by two distinct modules at each site.
As an example, in one laboratory using a P + P conﬁgu-
ration, the calcium CV on each module was approximately
1%, but the overall (combined) CV was 2.3% because of a
diﬀerence in the median values from the modules (nearly
5%).Thebetween-dayCVstakenasthemedianfromtheﬁve
laboratories were below 3%. Typical CVs were 1% to 2% for
the enzymes, substrates, and electrolytes, and 1% to 4% for
the speciﬁc proteins, drugs, and urine methods. Of all the
analytes, only bicarbonate with a CV of 7.2% exceeded the
performance criteria (3%).
As an additional quality indicator of imprecision, one
laboratory determined the functional sensitivity for the fer-
ritin assay; the corresponding precision proﬁle is shown in
Figure 3. Functional sensitivity is deﬁned as the concentra-
tion at which the between-day CV reaches 20% [4]. At the
manufacturer-deﬁned lower detection limit of 15µg/L (or
5µg/L,usingtheincreasedsamplevolumererunfeature),the
between-day CV was just 14% (or 12%).
3.2. Drift
With the exception of bicarbonate, no drift eﬀects were ob-
servedinanyofthe16methodstestedoveraneight-hourpe-
riod. Bicarbonate showed a drift over eight hours of approx-
imately 5% (the decline was less than or equal to 2mmol/L).
For all four analytes selected to test drift after 24 hours with-
out additional priming on the D-module, the recovery was
between 95 and 105%.
3.3. Analyticalrangelimits
The manufacturer’s claims for linearity ranges were veriﬁed,
to the extent possible, for the methods tested in serum and
urine as indicated in Tables 3 and 6. Linearity on D- and P-
modules were comparable.
3.4. Carry-over
Sample-related carry-over [7] was tested on P-module with
analytes having a wide physiologic range (CK and ferritin)
and with urine versus serum for creatinine and albumin.
The ratio for the high and low serum analytes was 200:1;
for urine/serum creatinine, 140:1; for serum/urine albumin,
10000:1. No signiﬁcant carry-over eﬀect as deﬁned by the
expected performance criteria was observed when the diﬀer-
ence from the ﬁrst to the ﬁfth sample was compared to the
imprecision of the method.
Because MODULAR P- and D-modules depend on
reusable cuvettes, probes, and stirrers for analysis, we also
looked for evidence of reagent-dependent carry-over [8].
There was no relevant reagent-dependent cuvette carry-over
(lower than twofold standard deviation) observed between
the triglycerides and lipase assays. When “evasion” (a feature
which prevents carry-over by preprogrammed additional
washing of probes and stirrers between pipetting of speciﬁed
tests) was activated as recommended by the manufacturer,
reagent-dependent carry-over caused by the reagent probes
or the stirrers could not be detected between triglycerides
and lipase. No phosphate carry-over was observed.
3.5. Interferences
Up to a concentration of 1000mg/dL of Intralipid, none of
the 18 methods tested for lipaemia interference showed a
bias of more than 10% (the expected performancecriterion).
From the 19 methods tested with bilirubin, four meth-
ods yielded interferences of more than 10%: cholesterol
(220µmol/L), enzymatic creatinine (550µmol/L), magne-
sium(340µmol/L),andtotalprotein(430µmol/L).Fromthe
16methodstestedwithhaemoglobin,sevenmethodsshowed
interferences: AST, LDH, and potassium at low haemoglobin
concentrations (<50mmol/L); the other four at higher con-
centrations: CK (120mmol/L), iron (120mmol/L), triglyc-
erides (250mmol/L), and lipase (235mmol/L, the latter on
D-module only).
3.6. Accuracy
Three procedures were used to establish comparability
among the ﬁve participating laboratories and to assess ac-
curacy. First, as indicated in Table 3,t w oc o n t r o ls e r af r o m
the manufacturer were distributed. Ten of the assigned val-
ues were established by reference methods used by the Ger-
man Society of Clinical Chemistry; the values were unknown
to the participating laboratories. From all 17 methods tested,
the median recoveries were within the accepted range of 95%
to 105%. Second, for the standard reference materials (CRM
for enzymes and NIST for substrate and electrolyte meth-
ods), nine of the ten methods tested were within 5% of the
target values; the median recovery for cholesterol was 106%.
Third, a total of 149 method comparisons were done.
A condensed version of the method comparisons was ob-
tained by plotting the slopes (ordinates) versus the intercept
in percent of the upper medical decision level (abscissas).
Few methods exceeded 5% (the acceptance criteria) on any
axis. Figure 4a shows the comparisons of the D- versus P-
modules; 54 of 57 methods (all but lipase, creatinine, and
CRP) met the acceptance criteria. Figure 4b shows the com-
parisons of the enzyme, substrate, and electrolyte data from
the P-module versus the laboratories’ routine methods; 50
of 72 methods met the acceptance criteria. Deviations aboveMODULAR ANALYTICS 15
Table 5: Expected performance criteria.
Quality characteristic Expected performance
Imprecision at the medical
decision level
Within-run CVs:
enzymes and substrates 2%
ISE 1%
speciﬁc proteins, therapeutic drugs, drugs of abuse and general chemistries in urine 4%
Between-day CVs:
enzymes and substrates 3%
ISE 2%
speciﬁc proteins, therapeutic drugs, drugs of abuse and general chemistries in urine 6%
Imprecision routine
simulation
CV deviations from reference (batch) to random (simulation) part:
enzymes/substrates ∆CV ±1.0%
ISE ∆CV ±0.5%
proteins/drugs/urine methods ∆CV ±2.0%
Drift Systematic deviation from the initial value less than 5%
Analytical range limits Manufacturer claims must be fulﬁlled
Diﬀerences between the measured and target values from the dilution series are below 5%
In the low concentration range the absolute diﬀerences are judged with respect to the diagnostic
relevance
Carry-over Less than 2 standard deviations of within-run imprecision or less than 5% of the diagnostic deci-
sion level
Interference Deviation between baseline and measured value less than 10% [9]
Recovery of assigned value
in control materials
Deviation from the assigned value:
for enzymes, substrates, and ISE ≤5%
for proteins/drugs/urine methods ≤10%
Method comparison Slope:
deviation from identity line ≤±5% (10%)
Intercept:
deviation from diagnostic decision level ≤±5% (10%)
(values in brackets for proteins/drugs/urine methods)
Scatter around the regression line:
median distance at the percentile 95 (md95) [14]
deviation from diagnostic decision level ≤10%
The ISE-methods should not diﬀer by more than 5% in the concentration range:
120–180 mmol/L (Na)
2–9 mmol/L (K)
80–130 mmol/L (Cl).
5% on at least one axis were found for t-amylase, AST, CK,
CK-MB (activity), lipase, cholesterol, creatinine-Jaﬀe, glu-
cose, HDL cholesterol, uric acid, calcium, bicarbonate, iron,
magnesium, chloride, and sodium (see Table 7 [14, 15, 16]).
Figure 4c shows the comparisons of the urine and homoge-
neous immunoassay methods for the P-module versus the
laboratories’ routine methods; 15 of 20 methods (all but fer-
ritin, HbA1c, IgM, myoglobin, and theophylline) met the ac-
ceptance limits.
The scatter around the regression line, expressed as
median distance 95 (md95) [17], was acceptable in most
comparisons. Of the 92 comparisons done versus non-
MODULAR methods, 13 yielded an md95 greater than
10% of the diagnostic decision level (ALP, CK-MB, li-
pase, creatinine-Jaﬀe, creatinine-enzymatic, phosphate, α1-
microglobulin, CRP, ferritin, haemoglobin A1c, myoglobin,
digoxin, albumin in urine).
3.7. Functionalityandpracticability
Over all laboratories, the routine simulation experiments in-
cluded approximately 15500 samples and produced 114000
test results. Increased imprecision of the results in the ran-
domised phase (Table 4, “Precision in a simulated routine
run”), taken as one measure of functionality, was slightly16 Journal of Automated Methods & Management in Chemistry
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Figure 2: Imprecision in a simulated routine run, distribution of batch ((a), (c), (e), (g)) and random ((b), (d), (f), (h)) CVs for diﬀerent
analyte groups. (a), (b) Enzymes (117 CVs, 9158 results, 13 analytes). (c), (d) Substrates (180 CVs, 16165 results, 15 analytes). (e), (f)
Electrolytes (136 CVs, 15006 results, 8 analytes). (g), (h) Proteins, TDMs (80 CVs, 2351 results, 27 analytes).
higher(averagelessthan1%) thanthereference,asexpected,
but the diﬀerences were within the acceptance limits as de-
ﬁned by the study participants. Most deviations from the ac-
ceptance limits were due to expected causes such as analyte
instability or low analyte concentration of the sample. One
hardware problem, leaks in reagent sensor connectors, wasMODULAR ANALYTICS 17
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Figure 3: Functional sensitivity for the ferritin assay.
detected as a result of CVs exceeding the acceptance limits.
(This problem was subsequently remedied.) At all labora-
tories, MODULAR handled “provocations” as designed. For
example,whenreagentsweredepletedwhilerunning,MOD-
ULAR switched to another bottle of equivalent reagent, ei-
ther on the same module or on another available module; if
no other reagent was available, MODULAR saved the sam-
ples in the rerun queue and alerted the operator to the prob-
lem, allowing for eﬃcient resolution. When samples with in-
suﬃcient volume (or empty sample cups) were encountered,
MODULAR detected the problem, alerted the operator, but
continuedrunningtheremainderofitsworkloadwithoutin-
cident. MODULAR processed reruns automatically, diluting
samples or decreasing sample volume if needed, according to
user-deﬁned limits and application technical limits.
The practicability [11] of MODULAR was compared
to the existing situation in each laboratory using a ques-
tionnaire. The ratings from all participating laboratories for
hardware, software, and lab integration are shown in Table 8.
Higher ratings (7 to 10) were given more frequently for
MODULAR than for the existing laboratory situation.
In Figure 5, the conﬁgurations of the MODULAR sys-
tems at three representative study sites are displayed, along
with the distribution of the test requests per analyte per-
formed by each module. Note that each site conﬁgured its
system diﬀerently. As shown, lab A ran a total of 31 tests on
MODULAR; lab B, 30 tests; lab C, 40 tests. Lab A used 12 of
16D-modulechannelswith11analytesduplicatedonD-and
P-modules while lab B used all 16 D-module channels with
6 analytes duplicated on D- and P-modules. Lab C, a dou-
ble P-module conﬁguration, assigned 28 of 37 tests to both
modules. Many common chemistry tests were on all three
systems, but several analytes were unique to each site. Lab A
included lactate, haptoglobin, and cholinesterase; lab B in-
cluded urine/CSF protein, haemoglobin A1c, and lipase; lab
C included a variety of speciﬁc proteins.
To compare the eﬀectiveness of MODULAR versus a
combination of a Roche/Hitachi 747 plus a Roche/Hitachi
917, one operator from lab A performed the identical work-
load (a typical 16-hour period’s work) in real time. As
shown in Figure 6, 90% of 141 ﬁve-position racks (602 sam-
ples) run on MODULAR had rack-processing times (sample
rack placement on MODULAR to results available) of less
Table 6: Analytical ranges, manufacturer claims.
Analytes Module Units
Manufacturer
claim
Enzymes
AST D/P U/L 800
CK D/P U/L 2300
Substrates
CHOL D/P mmol/L 21
CHOL-HDL P mmol/L 4
CREA J D/P µmol/L 2200
GLU D/P mmol/L 42
TP D/P g/L 150
UA D/P µmol/L 1500
Proteins
CRP D/P mg/L 3–240
FERRI P µg/L 15–800
IGA P g/L 0.5–8
IGG P g/L 3–35
IGM P g/L 0.25–6.5
MYO P µg/L 3–560
Electrolytes
CA D/P mmol/L 5
CO2 D/P mmol/L 45
FE D/P µmol/L 180
CL ISE mmol/L 250
K ISE mmol/L 100
NA ISE mmol/L 250
Urine
A1M U P mg/L 2–200
ALB U P mg/L 3–400
CA U P mmol/L 13
CREAenz P µmol/L 35500
CREA J UP µmol/L 57500
PHOS U P mmol/L 92
UA UP µmol/L 16000
UREA U P mmol/L 1300
CL U ISE mmol/L 250
K U ISE mmol/L 100
NA U ISE mmol/L 250
than 30 minutes. In contrast, the comparable ﬁgures for the
Roche/Hitachi 917 and the 747 were 84% (27 of 32 racks)
a n d6 9 %( 6 6o f9 6r a c k s ) ,r e s p e c t i v e l y .
Figure 7 displays the sample processing time (sample bar
code registration on MODULAR to results available) at site
B as the actual laboratory workload was performed. The
spikes in the graph, corresponding to longer sample pro-
cessing times (approximately 30 minutes), were associated
with automatically rerun samples. Detailed analysis of re-
run tests from approximately 3000 test requests run on fresh
randomly selected samples showed that roughly 30 (1%) of
the tests were rerun. Of these, 21 (70%) were related to lab
policy (e.g., critical values that laboratories have tradition-
ally repeated before reporting), and 9 (30%) were caused by
analytical limitations (including dilutions, error codes, etc.).18 Journal of Automated Methods & Management in Chemistry
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Figure 4: Method comparisons—summary of slope and intercept (a) D-module versus P-module, 57 comparisons, (b) enzymes, substrates,
and electrolytes (P-module versus routine method, 72 comparisons), (c) proteins, TDMs, and urine analytes (P-module versus routine
methods, 20 comparisons).MODULAR ANALYTICS 19
Table 7: Method comparisons exceeding the acceptance limits.
Analyte Unit Lab Regression analysis Comment
Slope Intercept md
(95)
Amylase total U/L 1 1.14 −0.96 2.97 X = UV-method
AST IFCC w/o PYP U/L 4 1.09 0.06 2.52 X = optimised (DGKC) method
CK NAC U/L 13 1.06 −0.29 5.76 Oneofﬁvelabs,onlyonP-module,noton
D-module, calibration eﬀect
CK-MB U/L 2 1.06 1.17 25.97 Only one lab, high scatter above 50 U/L
Lipase U/L 1 0.86 5.60 19.79 X = method from Sigma. Similar results
described in [14]
Cholesterol mmol/L 4
2
1.09
1.11
−0.05
−0.15
0.19
0.16
Two of ﬁve labs, download experiments
yielded slopes from 0.94 to 1.06
Creatinine Jaﬀ´ e µmol/L 1
4
2
0.92
0.91
0.94
−23.08
−24.96
8.64
15.32
20.75
16.68
Lab 1 + 4: no compensation by an abso-
lute term of 27 µmol/L during calibration
Glucose HK mmol/L 13 1.10 0.01 0.63 One of ﬁve labs, download experiment
yielded a slope of 1.04
HDL cholesterol mmol/L 2 0.96 0.09 0.05 At medical decision level (0.9mmol/L)
methods diﬀer by about 6%
Uric Acid µmol/L 13 1.06 −4.28 8.25 At medical decision level (340µmol/L)
methods diﬀer by 4.7%
Calcium mmol/L 3 0.94 0.05 0.15 Calibration eﬀect (stability) on the rou-
tine instrument
Bicarbonate mmol/L 13 0.84 1.87 1.99 Analyte instability. Comparison must be
performed at the same time
Iron µmol/L 1 1.10 −0.12 0.80 X = Cobas Integra 700, diﬀerence in stan-
dardisation, correction done
Chloride ISE mmol/L 4
13
2
0.94
0.90
1.11
3.67
8.40
−11.04
4.76
2.49
3.15
Between 80 and 130mmol/L the methods
diﬀer less than 5%
Sodium ISE mmol/L 13
3
1.10
1.06
−16.80
−5.48
2.19
5.46
Between 120 and 180mmol/L the meth-
ods diﬀer less than 5%
Magnesium mmol/L 13 1.10 −0.04 0.055 X = calmagite method, MODULAR
x y l i d y lb l u em e t h o dt r a c e db a c kt oA A S
Ferritin mg/L 2 1.19 1.17 73.33 X = method from Beckman Access, LPIA
method correlates well to the Enzymun
and Elecsys method [15]
HbA1c% % 4 0.81 1.53 0.52 X = Diamat HPLC method, refer to [16]
IgM g/L 4 0.81 0.08 0.14 X =CobasIntegra700turbid.method,re-
cently compared versus a nephelometric
method yielding 20% lower results
Theophylline µmol/L 4 0.89 −3.18 6.96 X = FPIA method
Myoglobin µg/L 2 1.12 −4.67 27.02 Diﬀerent standard sets on MODULAR
and routine instrument
Table 8: Questionnaire results as percent of total responses. Rating 1–3 = suggests improvement needed, 4–6 = meets lab requirements, 7–10
= exceeds lab requirements.
Rating Hardware (36 questions) Software (75 questions) Lab integration (77 questions)
1–3 4–6 7–10 1–3 4–6 7–10 1–3 4–6 7–10
MODULAR 84 74 5 34 35 4 64 45 0
Current analysers(s) 66 33 110 62 28 86 23 020 Journal of Automated Methods & Management in Chemistry
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Figure 5: Distribution of test requests per analytes and module for (a) laboratory A, (b) laboratory B, (c) laboratory C.MODULAR ANALYTICS 21
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Figure 6: Rack processing time for MODULAR versus Roche/Hitachi 747 and Roche/Hitachi 917, laboratory A.
The reruns were all performed without operator interven-
tion.
Lab B ran its workload in two diﬀerent ways: as a sin-
gle large batch (818 samples, 4935 tests) over 175 minutes
simulating a commercial laboratory setting and as multiple
smaller batches over about ﬁve hours representing a hospital
central laboratory. Both types of situations were easily man-
aged and completed without incident. To test the eﬀective-
ness of the STAT port, lab B introduced STAT samples while
the system was in operation processing the normal morning
workload. Table 9 provides the details on how the STAT sam-
pleswereprocessed.Inbothcases,all5samples,withvarying
testrequestsasindicated, werecompleted within 13 minutes.
Figure 8 presents the throughput for the double P-
module conﬁguration from lab C. Continuous loading of
1495 samples with 9735 test requests (from 40 test methods)
resulted in a throughput of about 250 samples per hour.
Routine daily maintenance required a total of 40 min-
utes (40–60 minutes if reagent preparation was included).
However, as noted in Table 10, combining software fea-
tures of parallel module maintenance, single module main-
tenance during operation, and automatically linked mainte-
nance functions, lab B could perform maintenance such that
the instrument was totally unavailable for only 13 minutes;
during the other 27 minutes of maintenance, ISE tests plus
one of the two modules were available to perform analyses.
4. DISCUSSION
The overall performance of MODULAR met (and, in some
areas, exceeded) the needs and expectations of laboratory
personnel. Expected performancecriteria wereestablished to
help screen and manage the vast amounts of data generated.
In almost all cases where some of the analytical methods did
not meet preset expected performance criteria, the problems
did not occur in all laboratories, and the methods met the
manufacturer’s claims. Furthermore, on careful review, none
of the apparent shortcomings were deemed clinically signiﬁ-
cant.
4.1. Imprecision
For the electrolytes and the substrates, the within-run CVs
for the results of both the control materials and human
specimens were well within the acceptance limits. Rou-
tine simulation experiments revealed that the within-run
CVs were systematically slightly better for batch analy-
sis than those performed in random mode. The diﬀer-
ences in CVs of these two modes, however, were within
the acceptance limits. It can be expected that the impreci-
sion obtained on a MODULAR system is higher than on
a single analyser since the results could be generated on
diﬀerent analytical units, each requiring separate calibra-
tion.22 Journal of Automated Methods & Management in Chemistry
Table 9: STAT sample processing during morning run (lab B). (The bold words denote P-module, the regular words denote D-module, and
the underlined words denote ISE-module.)
Rack Samples (requests over three modules) Time (on analyser to last result)
1
1 = BUN, CREA,N a ,K
13 min
2 = ALP, ALT, AMYL,A S T ,B U N ,C O 2,C R E A ,DBIL,T B I L ,N a ,K ,C l
3 = BUN, CREA,N a ,K
4 = BUN, CK, CO2, CREA,N a ,K ,C l
5 = BUN, CK, CO2, CREA,N a ,K ,C l
2
1 = CA, PHOS, Na,K
13 min
2 = CA, PHOS, Na,K
3 = BUN,N a ,K
4 = BUN, CO2, CREA, GLU,N a ,K ,C l
5 = ALB, ALP, ALT, AST, CK, L D ,T B I L ,N a ,K
The total imprecision obtained on a MODULAR system
was expected to be equivalent to the combination of single
analysers. The total variance can be estimated in a so-called
nested design by
SDMODULAR =

sd2
MODULE +sd2
RUN +sd2
REP,( 1 )
where REP denotes repetition.
Ad i ﬀerence of ±5% between two modules was deemed
acceptable. It has previously been shown that this was a
realistic and achievable goal [18] for the earlier genera-
tions of Roche/Hitachi analyser. Based on the data from the
drift experiment, we ascribe the relatively high bicarbonate
between-day CV (7.2%) to analyte instability rather than
method imprecision.
4.2. Functionalsensitivity
Reliable measurements at high as well as low plasma ferritin
levels are important for clinical decision making. Ferritin
could be determined down to the manufacturer-speciﬁed
limit of 15µg/L, using the routine application on MODU-
LAR; the CV at this concentration was 14%. However, if the
concentration is less than 15µg/L, MODULAR does an au-
tomatic rerun with increased sample volume. This enabled
the functional sensitivity to be extended to less than 5µg/L.
This means that the ferritin assay can be used conﬁdently to
diagnose iron deﬁciency.
4.3. Analyticalrangelimits/interferences
The acceptance criteria for linearity of the measuring range
were fulﬁlled for all analytes. For standard spectrophotomet-
ric methods, the most frequent sources of interference are
haemolysis, hyperbilirubinaemia, and lipaemia (turbidity).
Of note is the fact that MODULAR, like its predecessors in
the Hitachi line, is capable of estimating the level of these
interferents from the measurement of “serum indices,” an
additional test based on absorbance readings taken at mul-
tiple wavelengths of each sample diluted with saline [19].
In the case of AST, LDH, and K, the positive interference
in haemolytic specimens is not due to haemoglobin itself,
but due to these substances being liberated from erythro-
cytes during haemolysis. In a similar way, the increase in
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Figure 7: Sample processing time including automatic reruns
(from bar code reader registration to result), laboratory B.
iron with increasing haemolysis is not a true interference but
a reﬂection of the haemoglobin-bound iron. Even though
the CK reagent contains inhibitors of adenylate kinase (AMP
and diadenosine pentaphosphate), at high enough levels of
haemolysis (120mmol/L), this inhibition is overcome and
the apparent CK activity increases.
4.4. Accuracy
As noted in Results, accuracy of the methods on MODULAR
wasestablishedinthreediﬀerentways.Inallﬁvelaboratories,
the recoveries of both control materials for the 17 methods
tested were within 5% of the assigned values. Second, for the
certiﬁed reference materials (NIST and CRM), all but two of
the results (both cholesterol) were within 5% of the assigned
value. In the case of cholesterol, the higher than expected re-
coveries were probably due to the value assigned to the cal-
ibrator. When repeated with a new calibrator, the recoveries
of the NIST materials went from 99–108% to 96–103% (all
within the 95–105% acceptance criteria).
Third, 65 out of 92 method comparisons performed ver-
sus existing non-MODULAR methods gave slopes and in-
tercepts that were within the acceptance limits. For 7 an-
alytes, the comparison methods were intrinsically diﬀer-
ent (e.g., diﬀerent substrates for amylase), which explains
the higher deviations from, and higher scatter around, theMODULAR ANALYTICS 23
regression line. The deviations of the remaining 20 methods
were caused by diﬀerent standardisation, calibration eﬀects,
analyte instability or narrow range of data points; detailed
explanations are given in Table 7.
4.5. Functionalityandpracticability
When evaluating new analytical systems, it is important to
determine whether the new systems can achieve their poten-
tial in real operating laboratories, where a number of diﬀer-
ent variables come into play. The number of interactions in-
creasessubstantiallyasthenumberofdiﬀerentchemistrytest
methods run on an analyser increases. It is diﬃcult, if not
impossible, to detect all such possible combinations utilising
traditional evaluation methods, but the opportunity to de-
tect (and correct) such situations increases greatly when the
newsystemisevaluatedunderroutinelaboratoryconditions,
as we did in the routine simulation experiments [10]. For ex-
ample, the occasional leaks in the reagent sensor connectors
that were noticed during these experiments (as deviant re-
sults) were repaired by a hardware modiﬁcation.
According to the questionnaire results, MODULAR met
laboratory requirements and oﬀered an improvement over
the current laboratory situation in the area of lab integra-
tion as well as in hardware and software related attributes.
The main advantages of the system cited were: eﬃciency
gained through workstation consolidation and automatic re-
run, ease of use and training, high throughput combined
with high reliability of results, and versatility oﬀered by an
extensive test menu and the ability to expand the system.
The main perceived shortcomings mentioned were the in-
ability to reload reagent during operation (advantageous,
even if not entirely necessary, for most labs), the need to put
a module back into service more quickly once oﬄine trou-
bleshooting was completed, and the desire for easier access
to internal parts for operator maintenance. Shortly after the
evaluation was completed, the ﬁrst two shortcomings were
addressed by software changes. An additional point of dis-
cussion was the potential need for some back-up analytical
system if the track, or another central part, of MODULAR
failed. The need for such back-up systems is lab-speciﬁc and
depends on service levels oﬀered, availability of other instru-
mentation in the central lab, access to satellite labs, etc. How-
ever, based on the experience from this multicentre trial we
can say with conﬁdence that the probability of a central fail-
ure of MODULAR is very low.
Many discussions on laboratory automation today focus
on workstation consolidation—combining a number of tra-
ditionallydistinctmethodologiesonasingleanalyser[20,21,
22]. For example, in one study, seven workstations were re-
duced to two “multi-functional” analysers, oﬀering photom-
etry, turbidimetry, ion selective electrodes, and ﬂuorescence
polarisation, with concomitant reductions in turnaround
time,errorsandsamplesplitting[23].MODULARoﬀersthis
kind of workstation consolidation, with over 100 methods
available (corresponding to more than 80 analytes), encom-
passing electrolytes, routine chemistry testing, speciﬁc pro-
teins, TDM, toxicology, and other homogeneous immunoas-
says. Furthermore, MODULAR provides additional ﬂexibil-
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Figure 8: Throughput for large batch workload (ISE-, P1-, P2-
module conﬁguration), laboratory C.
ity and capabilities. MODULAR allows STAT samples to be
processed, for the full repertoire of testing, while processing
its regular workload. This may enable some laboratories to
incorporate separate STAT laboratories into a single MOD-
ULAR workstation in their main laboratories. Additionally,
if it turns out that one has initially underestimated the test
repertoire or throughput required, one has the ﬂexibility of
adding modules to the system as needed.
Perhaps a more important criterion for evaluating a sys-
tem’s eﬀectiveness today is the time it takes to complete its
analyses.Whatlaboratoriesreallyneedtoconsideristhetime
it takes to get results back to the ordering physician. Looking
atthedatafromlabA,weknowthat,formorethan90%ofits
samples, the rack processing time (i.e., the time from when
the operator placed the 5 samples on MODULAR until the
analyseswerecompleted)waslessthan30minutes.Inthisre-
gard, MODULAR met or exceeded the laboratories’ require-
ments. The time to results for samples with requests on both
the 917 and 747 is in fact even longer than presented here be-
cause only the sum of the processing times without the time
for transfer between individual systems was considered. The
throughputofMODULARwasquiteacceptablewhetherone
was running the system as a commercial laboratory (simu-
lated as one large-batch run in this study), or as a hospital
central laboratory (in multiple smaller batches), or as sam-
ples arrive in the laboratory. Lab C was able to meet its ex-
pectations and requirements for workﬂow, too, even though
it processed a large number of samples with many diﬀerent
analytes. Their choice of a P+P conﬁguration, with duplica-
tion of 28 analytes, enabled them to process samples eﬀec-
tively in serial, parallel, and serial/parallel fashion.
However, when considering the time it takes to complete
analyses on a modern system, one must also consider the
time it takes to do reruns, to process STAT samples, and to
resume testing when reagents need to be replenished unex-
pectedly. In Figure 6 the samples whose processing time is24 Journal of Automated Methods & Management in Chemistry
Table 10: Daily maintenance procedure maximising operating time (lab B).
Maintenance period Maintenance type Analyser status Available tests Time required (min)
1 Parallel maintenance1 Standby 0 13
2 D-module maintenance2 P-module operational ISEs + 17 15
3 P-module maintenance3 D-module operational ISEs + 16 10
1 includes D-module bath exchange, ISE- and P-module air purge, ISE prime, sample probe clean and adjust, ISE calibration.
2 includes air purge, mechanical check, reagent prime, photometer check, adjust stirrers, prime new reagents, clean rinse nozzles.
3 includes P-module bath exchange, photometer check, clean and adjust stirrers and reagent probes, clean rinse nozzles.
longer than the typical 20 minutes are seen as peaks. These
were actually automatic rerun tests which represent one of
the major advantages of MODULAR software, internal track
system connecting modules, and input, holding, and output
buﬀers. By automatically processing the rerun tests, the sys-
tem does, in a much more eﬃcient way, what a human oper-
ator would normally be required to do, freeing the operator
and allowing the system to optimise sample processing. Sim-
ilarly, when reagents are depleted, MODULAR automatically
usesequivalentreagents,evenifitmeansshuntingsamplesto
anothermodule;whenSTATsamplesareintroducedtheyare
processed according to computer-optimised scheduling. The
combination of the fast, eﬃcient, hands-oﬀ sample process-
ingwiththelargerepertoireoftestsmakesMODULARavery
eﬀectivesystem.WiththeISE+D+Pmoduleconﬁguration,
the system can oﬀer as many as 63 diﬀerent chemistry tests
simultaneously. Thus, the typical sample processing times of
20 minutes and rack processing times of 30 minutes reﬂect a
potentially very large proportion of a laboratory’s total work
andmostsamples’completetestrequests.Thatis,whensam-
ples arrive in the MODULAR output buﬀer, they are likely
totally completed. Laboratory B calculated that MODULAR,
even without its maximised test repertoire, covered more
than 90% of its test requests in the chemistry laboratory.
In conclusion, MODULAR performed well technically
and operationally during the evaluation. The workload and
the workﬂow studies showed the ability of MODULAR to
handle the workload and workﬂow of multiple instruments
with over 100 methods. The total testing time on MODU-
LAR was faster than the individual analysers by 30 minutes.
Thus, MODULAR begins to constitute a “third-generation
analyser,” whose features include tracks that move samples
between modules and a computer that handles scheduling
and other automated tasks [22].
Further progress toward total consolidation has occurred
since the completion of this evaluation. For immunochem-
istry laboratories, Roche introduced MODULAR ANALYT-
ICS E170 module (E170), based on the well-established elec-
trochemiluminescence methodology of the Elecsys analyser
[24]. However, major advancement occurred when Roche
launched MODULAR ANALYTICS Serum Work Area (IN-
TEGRATED MODULAR ANALYTICS in the US market),
which allowed E170 modules and ISE-, D-, and P-modules
to be combined on one platform, thereby consolidating het-
erogeneous immunoassays (E170) with the electrolyte, sub-
strate, enzyme, and homogeneous immunoassay methods
described in this paper.
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